MedTrace Logo

Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing

NCT03929653 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-04-29

No results posted yet for this study

Summary

This study seeks to evaluate the clinical value of the personalized therapy model with the guidance of Molecular Tumor Board (MTB) after Next Generation Sequencing(NGS), and to track patient outcomes.

Conditions

  • Solid Tumor, Adult

Interventions

OTHER

Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing

This study is to observe this therapy model outcomes

Sponsors & Collaborators

  • Tianjin Medical University Second Hospital

    lead OTHER

Principal Investigators

  • Haitao Wang · Tianjin Medical Unversity Second Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03929653 on ClinicalTrials.gov